In the latest update, a coronavirus vaccine candidate tested by American firm Pfizer and German biotech major BioNTech SE has been found to generate antibodies in people, a study showed. The research also said that the antibodies generated in participants after receiving two shots of the vaccine candidate were more than in patients receiving convalescent plasma from patients recovered from coronavirus infection. The study in the preprint server medRxiv mentioned the preliminary clinical data for the candidate vaccine -- nucleoside-modified messenger RNA (modRNA), BNT162b1.
"I was glad to see Pfizer put up their phase 1 trial data today. Virus neutralizing antibody titers achieved after two doses are greater than convalescent antibody titers," Peter Hotez, a vaccine scientist from Baylor College of Medicine in the US tweeted.
As of now, there is no approved vaccine for coronavirus infection all across the world. There are 16 vaccine candidates currently in late-stage clinical trials among the 140 vaccines in different stages of development to fight coronavirus, according to the World Health Organisation (WHO).
Among the frontrunners in the vaccine race, as identified by WHO, are the candidates developed by Oxford University - AstraZeneca and Moderna Inc. Moderna has also entered into a deal with Catalent for large-scale manufacturing of its vaccine candidate. Catalent is already in partnership with Johnson and Johnson as well as AstraZeneca. Sanofi, Inovio, Sinovac and CanSino are some of the major companies to have made significant progress.
The Hyderabad based Bharat Biotech's vaccine candidate COVAXIN had earlier this week received permission for advancing to human trials. COVAXIN is India's first vaccine candidate for COVID-19, developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). Human clinical trials are scheduled to begin across India in July.
Copyright©2021 Living Media India Limited. For reprint rights: Syndications Today